Clarigene^® SARS-CoV-2 CE-IVD

A CE-Marked RT-qPCR assay which detects the presence of  SARS-CoV-2 viral RNA

Benefits

• High accuracy with >99.9% specificity*
• Clinical sample testing presented 100% concordance when compared to gold standard reference**
• Excellent sensitivity and precision (LOD of 5 copies per reaction); results are in concordance with an international external quality assessment panel
• Dual viral RNA targets; SARS CoV–2 Envelope gene and Nucleocapsid (N) gene for a more reliable result
• Assay uses N and E gene targets which are SARS-CoV-2 specific, meaning no cross reactivity with other Coronaviruses
• Human RNase P control designed as a true RNA control for lower false negatives
• Internal control detects improper sample collection or poor-quality sample to give an invalid result, rather than giving a negative result
• Fast turnaround time after RNA extraction
• Simple and easy to set up
• High throughput options available

*In silico analysis did not identify any potentially amplifiable targets in other respiratory pathogens.

** 48/48 positive and 24/24 negative

For information regarding our ongoing rigorous viral surveillance program please see here.

Specifications

• Kit includes Mastermix, run controls, ROX, primers and probes
• Compatible with RNA extracted from upper respiratory specimens (such as individual or combined nasophyrangeal, oropharangyeal, nasal and mid-turbinate swabs, and nasopharyngeal aspirate)
• Assay can be easily adapted to robotic liquid handling
• 960 tests per kit for high throughput testing
• Compatible with qPCR machines capable of detection of FAM, VIC and Cy5 fluorophores

Why Choose Clarigene^®

• Low False Negatives

  Tests must include fail-safe controls that affirmatively report the presence of intact RNA and demonstrate success of all steps of the assay. A result of “no virus signal” is insufficient for clinical interpretation: controls must also say “The reaction worked as intended and would have found virus if present”. Many assays on the market use a RNase P control designed within a single exon and so detect both reverse-transcribed RNA and human genomic DNA, i.e., are unable to differentiate human genomic DNA from reverse-transcribed RNA. This inability can lead to false negative results where reverse transcription fails, but human DNA is amplified and interpreted as a successful, SARS-CoV-2 negative, test. Yourgene RNase P control is designed to span an exon boundary and hence does not detect human genomic DNA so is a true RNA control.

• High Accuracy
  
  N target is specific for SARS-CoV-2 and does not cross react with other Coronaviruses unlike some other assays on the market.
  
  
• Fast Turnaround Time
  
  Automation compatible kit format (CE-IVD) with easy to interpret data.
  
  
• Post-market surveillance
  
  Developing rigorous surveillance programs that can keep pace with the rapid nature of evolving strains relies on the use of bioinformatic tools, as well as traditional laboratory testing methodologies. Yourgene Health have developed a database monitoring (in silico) and wet laboratory testing workflow to complement the Clarigene^TM SARS-CoV-2 assay. This process allows us to be confident of the performance of the Clarigene assay in light of any so called ‘Variants of Concern’ (VOC).
  

Clarigene^® SARS-CoV-2 assay publications

1. Ilieva VI, Flynn EM, Marvin JMC, Szynkiewicz M, Morrissey C, et al. Novel CE-Marked SARS-CoV-2 IVD Assay Solves the Problem for Genomic DNA Contamination. Curr Trends Med Diagn Meth.2021 Feb 4.

Ordering Information